Carregant...
Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
BACKGROUND: Checkpoint-Inhibition has revolutionized the treatment for several entities such as melanoma and renal cell carcinoma. The first encouraging experience in ovarian cancer was reported for nivolumab, a fully humanized anti-programmed death-1 antibody. Pseudoprogression is a new phenomenon...
Guardat en:
| Publicat a: | World J Clin Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6682498/ https://ncbi.nlm.nih.gov/pubmed/31396474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5306/wjco.v10.i7.247 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|